Full-Time

Scientist I/II/Senior Scientist

Medicinal Chemistry

Posted on 8/27/2025

Hexagon Bio

Hexagon Bio

51-200 employees

Genomics-driven discovery of small-molecule inhibitors

Compensation Overview

$120k - $180k/yr

+

Menlo Park, CA, USA

In Person

Open to candidates within reasonable commuting distance to Menlo Park, CA; preference for local candidates who can start promptly.

Category
Biology & Biotech (4)
, , ,
Requirements
  • Scientist I: Ph.D. in organic or medicinal chemistry, and 0+ years postdoctoral and/or industry experience
  • Scientist II: Ph.D. in organic or medicinal chemistry, and 2+ years postdoctoral and/or industry experience
  • Senior Scientist: Ph.D. in organic or medicinal chemistry, and 4+ years postdoctoral and/or industry experience
  • Ability to perform complex multistep synthesis quickly, efficiently, and safely
  • Ability to effectively summarize and communicate research findings
  • Ability to work full-time onsite at Menlo Park, CA laboratories
Responsibilities
  • Structure-based and hypothesis-driven design of new ADC payload and linker-payload drug compounds
  • Multistep synthesis, purification, and characterization of new ADC payload and linker-payload drug compounds
  • May manage of aspects of a drug discovery program
  • May manage chemistry at a contract research organization

Hexagon Bio uses synthetic biology and data science to discover and develop new medicines by analyzing genomic data from thousands of species to find small molecules that inhibit disease-related proteins. Its proprietary algorithm searches genomes to identify lead compounds and its platform can quickly turn those molecules into candidates suitable for clinical development. The company blends computational biology, chemistry, and synthetic biology to move from genome data to drug candidates faster, and it leverages inexpensive sequencing to access diverse genetic information while producing leads in-house. Its goal is to build a steady pipeline of drug candidates and license them to larger pharmaceutical companies to advance through clinical trials and commercialization.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$183.6M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $77.3M Series B in 2024 funds preclinical ADC programs expansion.
  • Exponential metagenomic data growth enables discovery of diverse therapeutics first.
  • Licensing model monetizes platform via pharma partnerships across indications.

What critics are saying

  • Corteva JV diverts R&D from oncology to agriculture in 2024.
  • Synaffix and ADC Therapeutics advance superior payloads into clinic by 2025.
  • No Phase 1 candidates by mid-2026 triggers investor withdrawal.

What makes Hexagon Bio unique

  • Proprietary platform mines fungal genomes for novel ADC payloads overcoming resistance.
  • Builds 10x larger proprietary metagenomic database than public ones.
  • Combines data science, synthetic biology, and automation for rapid compound production.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Hexagon Bio who can refer or advise you

Benefits

Flexible Work Hours

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-5%
InvestorsObserver
Feb 13th, 2023
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules

Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules

Vator
Sep 23rd, 2021
The Column Group LLC invests into Hexagon Bio in $61M

Hexagon Bio has raised $61 million in funding led by Nextech, with participation from SoftBank, Casdin Capital and earlier investors The Column Group, 8VC and Two Sigma Ventures.

Business Wire
Sep 22nd, 2021
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

MENLO PARK, Calif.--(BUSINESS WIRE)--Hexagon Bio, a biopharmaceutical company mining microbial genomes to discover new medicines, has raised $61M to advance preclinical programs.

Finsmes
Sep 15th, 2020
Hexagon Bio Closes $47M Series A Financing

Hexagon Bio, Inc., a Menlo Park, Calif.-based biotechnology company turning nature's genomes into medicines, raised $47m in Series A financing

INACTIVE